Incretin drugs, including GLP-1 receptor agonists and DPP-4 inhibitors (which increase the level of active GLP-1 in vivo), are a new type of drugs for the treatment of type 2 diabetes (31, 32). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.